Home > Browse Research > Life Sciences > Pharmaceuticals > Research & Development

Research & Development: market research reports

The term research and development (R&D) refers to work that is done in order to better understand the nature, function or understanding of a topic or product in order to gain knowledge and find new applications for existing products or to develop new and innovative products. This is usually performed by corporations, government agencies, and research or academic institutions.

New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce.

In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.

Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.

Research & Development market research reports and industry analysis

China Pharmaceutical Guidebook Series (4) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Traditional Chinese Medicines and Natural Medi 5/20/2013 \| published by: Access China Management Consulting Ltd. ... a precise chemical structural formula, but also the indications of the majority of traditional Chinese medicines still can not been clearly described by the modern medical terminologies. How the Chinese drug authorities to administer the ... \| read more...	$750.00
China Pharmaceutical Guidebook Series (3) 2013 Edition Material and Clinical Trial Requirements of Application and Approval for Imported Drug Registration: A Guidebook of Registration Application for Imported Biological Products 5/10/2013 \| published by: Access China Management Consulting Ltd. ... behind the developed countries. The requirements of materials and clinical trials for registration application of biopharmaceuticals stipulated by the Chinese pharmaceutical authority are far from systematic and harmonized. In China, the pharmaceutical regulatory authority ----- ... \| read more...	$750.00
Anti-Obesity Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in ... \| read more...	$2,000.00
Osteoporosis Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ... \| read more...	$2,000.00
Anti-Tumor Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in ... \| read more...	$2,000.00
Hypertension Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ... \| read more...	$2,000.00
Blood Disease Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major ... \| read more...	$2,000.00
Mental Illness Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major ... \| read more...	$2,000.00
Lymphoma Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ... \| read more...	$2,000.00
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry 4/30/2013 \| published by: GlobalData ... the Pharmaceutical Industry report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 ... \| read more...	$2,995.00
Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players 4/29/2013 \| published by: GBI Research ... latest research “Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players”. Japan’s pharmaceutical industry is the second largest in the world, ... \| read more...	$3,500.00
Scientific Research & Development in the US - Industry Risk Rating Report 4/24/2013 \| published by: IBISWorld ... or otherwise, of the business operating environment'. The report looks at the operational risk associated with this industry. Three types of risk are recognized in our analysis. These are: risk arising from within the industry ... \| read more...	$1,020.00
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 196 drugs. Androgen Receptor Signaling Pathway In Oncology Drug Pipeline ... \| read more...	$5,621.25
Angiogenesis in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... number of ceased drugs over the last years amount to another 142 drugs. Angiogenesis In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs ... \| read more...	$5,621.25
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 207 companies plus ... \| read more...	$5,621.25
Bladder Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... treated early, the 5 year survival rate is 94%. There are today 98 companies plus partners developing 111 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number ... \| read more...	$3,746.25
Brain Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ... \| read more...	$5,621.25
Cancer Stem Cells Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today ... \| read more...	$5,621.25
Cellular Therapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... the accumulated number of ceased drugs over the last years amount to another 62 drugs. Cellular Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of ... \| read more...	$3,746.25
Colorectal Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years. There are today 299 companies ... \| read more...	$5,621.25
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 261 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists ... \| read more...	$5,621.25
FSH Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... FSH signaling which continues further downstream. Activation of PKA leads to phosphorylation of transcription factors like cAMP response element binding protein(CREB) and brings about chromatin remodeling by phosphorylating histone H3. It also enhances the activity ... \| read more...	$5,621.25
Gene Therapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... the accumulated number of ceased drugs over the last years amount to another 95 drugs. Gene Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of ... \| read more...	$5,621.25
Head and Neck Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... accumulated number of ceased drugs over the last years amount to another 42 drugs. Head And Neck Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ... \| read more...	$5,621.25
Hematological Cancers Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 631 hematological cancer drugs in 1265 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 196 drugs. Hematological Cancers ... \| read more...	$7,496.25

< prev 1 2 3 4 5 6 7 8 9 10 next >